Underneath that broad recovery, mRNA technology is struggling to prove its post-pandemic second act, with few equities representing the tension as effectively as Moderna Inc. (NASDAQ:MRNA). Total revenue for the first quarter of 2026 reached $389 million, up 260% year-over-year from $108 million in Q1 2025, with net product sales of $352 million, up 309%. However, during the first quarter of 2026, Susquehanna aggressively cut its Moderna, Inc. (NASDAQ:MRNA) holding by 96.6%, dumping roughly 1.56 million shares valued at $75 million. If you are looking for an AI stock that is more promising than MRNA and that has 10,000% upside potential, check out our report about this cheapest AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 YearsDisclosure: None.